What are the effects of erythrocyte (red‑blood‑cell) transfusion on the recipient’s blood?

Effects of Erythrocyte Transfusion on Recipient Blood

Beneficial Effects on Recipient Blood

Red blood cell transfusion increases hemoglobin concentration by approximately 1 g/dL per unit in average-sized adults, thereby enhancing oxygen-carrying capacity and blood volume. 1

Hematologic and Physiologic Benefits

• Increased oxygen delivery (DO2) to tissues occurs following transfusion, though importantly, this does not consistently translate to increased oxygen consumption (VO2) 2

• Rapid correction of hemoglobin and hematocrit levels represents the primary hematologic benefit, with one 300 mL unit of packed red blood cells typically raising hemoglobin by 1 g/dL 1

• Restoration of cell mass and blood volume occurs post-acute hemorrhage, which is critical for maintaining adequate perfusion pressure 2

• Improved functional capillary density has been demonstrated in microcirculation studies, though the clinical significance varies by patient 3, 4

• Regional tissue oxygenation improvements measured by near-infrared spectroscopy show increases in tissue beds following transfusion, particularly in patients with abnormal pre-transfusion oxygenation 3, 4

Clinical Symptom Relief

• Alleviation of anemia symptoms including dyspnea, fatigue, diminished exercise tolerance, and cardiac effects of severe anemia with critical oxygen delivery 2

Adverse Effects on Recipient Blood and Systems

Immunologic and Inflammatory Complications

• Transfusion-associated immunomodulation (TRIM) occurs as a consequence of donor leukocytes and inflammatory mediators affecting recipient immune function 2

• Transfusion-associated leukocyte microchimerism develops when donor leukocytes persist in the recipient, potentially causing long-term immunologic effects 2

• Alloimmunization risk is particularly concerning for patients eligible for organ transplantation, where red cell transfusions should be avoided when possible to minimize sensitization 1

• Febrile nonhemolytic transfusion reactions occur in 1.1% with prestorage leukoreduction and 2.15% with poststorage leukoreduction 2

Serious Acute Complications

• Transfusion-related acute lung injury (TRALI) occurs at a rate of 0.81 per 10,000 transfused blood components, with risk increasing with the number of transfusions and when plasma-containing products are used 2, 1

• Transfusion-associated circulatory overload (TACO) develops in 2-6% of transfused patients, causing fluid overload, pulmonary edema, and potentially requiring diuretic intervention 2

• Acute hemolytic transfusion reactions from ABO incompatibility carry a fatal risk of approximately 8 per 10 million RBC units transfused 2

• Acute transfusion reactions including fever occur commonly and require immediate clinical assessment 2

Infectious Risks

• Viral transmission risk remains extremely low but present: HIV (6.8 per 10 million units), HCV (8.7 per 10 million units), and HBV (28-36 per 10 million units) 2

• Bacterial contamination represents an ongoing infectious hazard despite screening protocols 1

Thrombotic and Organ Dysfunction

• Increased venous thromboembolism risk (OR 1.60) and arterial thromboembolism risk (OR 1.53) have been documented in cancer patients receiving transfusions 1

• Increased multiple organ failure (MOF) has been associated with RBC transfusion in critically ill patients 2

• Increased infection rates have been documented across multiple studies in transfused critically ill patients 2

• Increased mortality (OR 1.34) was observed in cancer patients receiving PRBC transfusions 1

Storage-Related Effects

• "Storage lesion" effects occur from banked blood, including reduced RBC deformability, altered adhesiveness and aggregability, reduction in 2,3-DPG and ATP, and accumulation of bioactive compounds with proinflammatory effects 2, 5

• Reduced posttransfusion viability of stored RBCs may compromise the intended oxygen delivery benefits 2

• Increased blood viscosity following transfusion may paradoxically decrease cardiac output in normovolemic patients, potentially offsetting oxygen delivery benefits 3

Critical Nuances in Transfusion Effects

Variable Individual Responses

• Highly variable inter-individual effects on tissue oxygenation occur, with the majority of studies (11 of 17) concluding that transfusion does not generally improve tissue oxygenation or microcirculation in patients with moderate anemia (hemoglobin 7-10 g/dL) 4

• Patients with abnormal pre-transfusion tissue oxygenation show improvement in oxygenation indices following transfusion, whereas those with normal baseline parameters often do not benefit 4

• Oxygen uptake fails to increase unless oxygen uptake/oxygen delivery dependency exists (severe anemia or strenuous exercise), as transfusion-induced viscosity increases may decrease cardiac output 3

Context-Dependent Outcomes

• No evidence of increased oxygen consumption despite increased oxygen delivery in most critically ill patients receiving transfusion 2

• Leukodepleted blood may reduce some adverse immunologic effects, with 76% of centers in recent studies using leukodepleted products routinely 2

• Portal hypertension exacerbation from volume expansion is a specific concern in patients with liver disease 1

Common Pitfalls to Avoid

• Overtransfusion leads to unnecessary exposure to all transfusion-related risks; single-unit transfusion with reassessment is recommended for hemodynamically stable patients 2, 1, 6

• Transfusing based solely on hemoglobin thresholds without considering clinical symptoms and tissue oxygenation status may result in unnecessary transfusions 2, 4

• Assuming transfusion always improves outcomes in moderate anemia (hemoglobin 7-10 g/dL) is not supported by evidence; restrictive strategies (threshold 7-8 g/dL) provide equivalent outcomes with reduced risk exposure 1

• Human error in blood component administration remains a significant risk factor requiring strict verification protocols 2